FDA Approves Wegovy for Cardiovascular Risk Reduction

The injection becomes the first weight loss medication to address life-threatening cardiovascular events.

The Food and Drug Administration has expanded the approved use of Wegovy (semaglutide) injection, making it the first weight loss medication authorized to help mitigate the risk of cardiovascular fatality, heart attack, and stroke in overweight adults with cardiovascular disease. The agency approval emphasizes the importance of incorporating Wegovy with a reduced-calorie diet and increased physical activity regimen.

“Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight,” said Director John Sharretts of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research. “This patient population has a higher risk of cardiovascular death, heart attack, and stroke. Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health.”

As the Lord Leads, Pray with Us…

  • For Director Sharretts to receive God’s wisdom as he heads his division of the FDA’s Center for Drug Evaluation and Research.
  • For Commissioner Califf to be discerning as he oversees the Food and Drug Administration.

Sources: Food and Drug Administration


Back to top